Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)

Draft guidance

Draft guidance (PDF version) (PDF 313 KB)

Draft guidance (online commenting)

Committee papers (PDF 7.3 MB)

Public committee slides (PDF 790 KB)

Final scope (PDF 193 KB)

Final stakeholder list (PDF 160 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 247 KB)

Equality impact assessment (Scoping) (PDF 124 KB)

Draft scope post referral (PDF 230 KB)

Draft matrix post referral (PDF 160 KB)